ArticleDiagnostic pathology2025
Artificial Intelligence-driven image analysis for standardised programmed death-ligand 1 expression evaluation in non-small cell lung cancer.
Article in Diagnostic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Human biomarker navigator.iMeta · 2026Review
- Nuclear PD-L1: an emerging oncogenic driver and promising therapeutic target in cancer.Journal of biomedical science · 2026Review
- Deep learning-based assessment of PD-L1 expression in NSCLC predicts outcome for patients treated with anti-PD-1 immunotherapy.Frontiers in immunology · 2026Article
- Redefining the Diagnostic and Therapeutic Landscape of Non-Small Cell Lung Cancer in the Era of Precision Medicine.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAccurate assessment of programmed death-ligand 1 (PD-L1) immunohistochemical (IHC) expression is critical for immunotherapy in patients with non-small cell lung cancer (NSCLC). Yet, interpreting its staining is challenging, time-consuming, and causes inter-observer variability, potentially mis-stratifying patients. This necessitates the development of an artificial intelligence (AI) model to effectively quantify PD-L1 expression. Hence, we developed an AI-based deep-learning approach to automatically assess PD-L1 expression in NSCLC using IHC 22C3 assay-stained whole slide images (WSIs).
methodsA total of 706 patients with NSCLC were included in this study and 1212 WSIs were collected from three distinct study cohorts. We accurately matched the hematoxylin and eosin-stained images of the internal dataset with the IHC WSIs. Foreground regions containing tumor tissue were extracted from WSIs, and a multi-granular multiple-instance learning approach employing instance embeddings with coarse and fine granularities was implemented to extract patch-level morphological features. A multi-grained expression interpreter-based model aggregated these features to stratify PD-L1 expression status.
resultsThe model showed strong interpretive ability in all three cohorts and wide applicability to different specimen types. The macro-average area under the receiver operating characteristic curve (AUC) were 0.940/0.915/0.944 for surgical specimens, 0.955/0.844/0.865 for biopsy specimens, and 0.901/0.958/0.883 for metastases.
conclusionThis study emphasizes the potential benefits of deep learning in automatically, rapidly, and accurately inferring PD-L1 expression from complex IHC images. It also showcases how AI frameworks can improve routine digital pathology workflows in current PD-L1 detection methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.